by Marie O'Brien | Feb 5, 2024 | News
ReNewVax is proud to participate in BioInfect 2024, a major conference set to commemorate the ten-year anniversary of the influential O’Neill Review on AMR. Hosted at The Spine in Liverpool’s Knowledge Quarter, the event will bring together key figures from academia...
by ReNewVax | Sep 20, 2023 | News
ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts. University spinouts are companies founded to commercialise innovative technologies, products or services that have originated from academic research conducted within universities....
by ReNewVax | Sep 20, 2023 | News
ReNewVax’s Chief Scientific Officer Dr Marie O’Brien is published in this autumn’s edition of Drug Target Review, sharing insights into our quest for a universal pneumococcal vaccine. ‘Why innovation is the key to unlocking a universal pneumococcal vaccine’ details...
by ReNewVax | Aug 2, 2023 | News
Since spinning out of the University of Liverpool, ReNewVax has started to build its scientific team and progressed its vaccine programme RVX-001 towards regulatory studies that will allow clinical trials to begin. CSO Dr. Marie O’Brien and CEO Dr. Neil Murray reflect...
by ReNewVax | Jul 12, 2023 | News
This month, European Pharmaceutical Review features a piece from ReNewVax’s Chief Executive Dr. Neil Murray for its Formulation issue. In the piece, Neil explores the importance of new bacterial vaccines in the context of antimicrobial resistance and examines how the...
by ReNewVax | Jun 22, 2023 | News
This month, North West Business Insider has named ReNewVax as one of thirty businesses across the region carrying out exciting work in their sectors. The Most Exciting Companies list features a range of companies shaking up their sectors, whether it be manufacturing,...
